Moderna (MRNA.O) received European regulatory approval for its dual flu-COVID vaccine on Tuesday, becoming the inaugural mRNA immunization to safeguard against both respiratory illnesses in adults 50 years and above.
This regulatory achievement offers Moderna a promising new income source as the biotechnology firm works to expand its portfolio beyond COVID-19 products, which reached peak revenues of $18.4 billion in 2022 before experiencing steep declines.
Key Takeaways
- First combined flu-COVID mRNA vaccine approved in Europe
- Targets adults 50+ with single-shot convenience
- US approval remains uncertain amid regulatory scrutiny
Market reaction & context
The European Medicines Agency’s Committee for Medicinal Products for Human Use endorsed marketing authorization for mCombriax, enabling Moderna to challenge separate flu immunizations from Sanofi and GSK 1. Trial results from 8,000 participants demonstrated the combination vaccine generated immune responses statistically non-inferior to current separate injections 2.
Moderna’s vaccine division has encountered challenges as COVID-19 demand stabilized, with respiratory vaccine revenues dropping 29% year-over-year in the third quarter of 2025. The dual-vaccine strategy could assist the company in recovering market position during seasonal immunization periods.
Detailed analysis
The mCombriax immunization includes messenger RNA instructions for producing proteins present on SARS-CoV-2 and three seasonal influenza virus variants: H1N1, H3N2, and influenza B Victoria lineage 1. Similar to current COVID and flu vaccines, the formulation will receive regular updates to correspond with circulating viral strains.
European health statistics referenced by regulators indicated over 281 million COVID-19 cases documented in the region through February 2026, while seasonal influenza generates up to 50 million symptomatic infections annually throughout the European Economic Area 1. The most frequent adverse effects encompass injection site discomfort, fatigue, muscle aches, and fever, with symptoms generally persisting three days 1.
Outlook & management quote
“The CHMP’s positive opinion represents an important milestone for respiratory virus vaccination and for Moderna,” CEO Stephane Bancel said in a statement 3. “Combination vaccines have the potential to simplify vaccination and support improved health outcomes.”
The European Commission must now confirm the recommendation before the vaccine becomes commercially available across EU member states. National health agencies will determine which vaccines to implement and establish recommendations regarding target demographics based on their particular epidemiological circumstances 1.
US regulatory uncertainty
Moderna’s route to US authorization remains complex after the FDA initially declined to evaluate the application in 2024, then changed direction following industry advocacy 4. The Trump administration’s selection of vaccine skeptics for senior health roles has generated additional regulatory ambiguity for mRNA technologies.
The company earlier withdrew its US submission after the FDA demanded supplementary data, then resubmitted the application with a confirmed August 2026 action date 5. This regulatory disparity between Europe and the US underscores different methodologies for combination vaccine assessment.
Conclusion
European authorization of mCombriax represents a major regulatory achievement for combination respiratory vaccines, potentially streamlining seasonal vaccination programs. Nevertheless, Moderna’s commercial performance will rely on price negotiations with individual EU member nations and eventual US market entry.
The vaccine constitutes Moderna’s fourth commercialized product in Europe, broadening its offerings beyond COVID-19 as the company aims to build a more comprehensive infectious disease portfolio.
Not investment advice. For informational purposes only.
References
1European Medicines Agency (February 27, 2026). “First combined COVID-19 and influenza vaccine for people 50 years and older”. European Medicines Agency. Retrieved April 21, 2026.
2Chris Dall, MA (February 27, 2026). “European regulators recommend approval of combined mRNA vaccine for flu and COVID”. CIDRAP. Retrieved April 21, 2026.
3Jennifer Boggs (February 27, 2026). “Moderna’s combo flu/COVID vaccine gets thumbs up in EU”. BioWorld. Retrieved April 21, 2026.
4Sam Becker (February 27, 2026). “Europe just approved a combined flu and COVID shot. Why hasn’t the US?”. Fast Company. Retrieved April 21, 2026.
5Kevin Dunleavy (February 27, 2026). “After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review'”. Fierce Pharma. Retrieved April 21, 2026.